Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026)

Regeneron Pharmaceuticals' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 21.53% year-over-year to $2.7 billion in Q1 2026; TTM through Mar 2026 was $2.7 billion, a 21.53% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 13.82% from the prior year.
• Accumulated Expenses retreated to $2.7 billion in Q1 2026 per REGN's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.0 billion in Q3 2025 and bottomed at $1.8 billion in Q3 2022.
• The 5-year median for Accumulated Expenses is $2.4 billion (2024), against an average of $2.4 billion.
• Across the five-year window, Accumulated Expenses dropped 12.84% in 2022 and soared 47.22% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $2.1 billion in 2022, then climbed by 13.68% to $2.4 billion in 2023, then climbed by 7.18% to $2.5 billion in 2024, then advanced by 13.82% to $2.9 billion in 2025, then dropped by 5.28% to $2.7 billion in 2026.
• Per Business Quant, the three latest REGN Accumulated Expenses figures stand at $2.7 billion (Q1 2026), $2.9 billion (Q4 2025), and $3.0 billion (Q3 2025).